Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neurotransmitter Agents: later-stage trial registry
3 of 3 indexed Neurotransmitter Agents trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 3 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Neurotransmitter Agents: 3 US clinical trials tracked, 3 recruiting.
Neurotransmitter Agents is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Theresa Jacob, PhD, MPH, running 1 of these trials.
Enrollment posture brief
Registry condition neurotransmitter-agents
OPEN 3 | RECR 100% | LATE 2 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Neurotransmitter Agents lists 3 open slots (100% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neurotransmitter Agents on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neurotransmitter Agents is recruiting above its size-band peers.
3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
Merz North America
NCT07122193
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
National Institute of Mental Health (NIMH)
NCT06511908
Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting
Theresa Jacob, PhD, MPH
NCT06752759
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Neurotransmitter Agents records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neurotransmitter Agents trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neurotransmitter Agents page
3 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Neurotransmitter Agents trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Theresa Jacob, PhD, MPH sponsors the most Neurotransmitter Agents trials on record, review their full trial history before evaluating a specific study. See Theresa Jacob, PhD, MPH's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neurotransmitter Agents condition card totals 3 registered trials; most-linked intervention nebulized ketamine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.